This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE . COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia 2010; 24: 298–308.
Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366: 1371–1381.
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1581–1588.
Villasboas JC, Ansell SM, Witzig TE . Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 2016; 7: 13260–13264.
Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant 2016; 51: 1268–1270.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375: 143–153.
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2015; 51: 443–445.
Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7: 76902–76919.
Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24–29.
Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077–2084.
Xia Y, Medeiros LJ, Young KH . Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev 2016; 30: 189–200.
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044–3051.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Boekstegers, AM., Blaeschke, F., Schmid, I. et al. MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD. Bone Marrow Transplant 52, 1221–1224 (2017). https://doi.org/10.1038/bmt.2017.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.107
This article is cited by
-
KLF9 promotes autophagy and apoptosis in T-cell acute lymphoblastic leukemia cells by inhibiting AKT/mTOR signaling pathway
Molecular & Cellular Toxicology (2023)
-
Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2019)
-
Pembrolizumab
Reactions Weekly (2018)